Radman Mostaghim, MD
Gastroenterology · Greenbelt, MDNPI 1720022023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gastroenterology clinicians in MD, where the typical reported total is $2,763.
Across 137 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$435
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$319
- Takeda Pharmaceuticals U.S.A., Inc.$287
- Bristol Myers Squibb$249
- Madrigal Pharmaceuticals$232
- Ardelyx, Inc.$209
- plus $923 from 16 others
Across 19 payments — averaging $4392.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$83K
What the payments were for
- Consulting fees$211%
- Food & beverage$2,57297%
- Education$482%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 18 | $435 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $319 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $287 |
| Bristol Myers Squibb | 22 | $249 |
| Madrigal Pharmaceuticals | 9 | $232 |
| Ardelyx, Inc. | 7 | $209 |
| AbbVie(2 entities) | 8 | $162 |
| Vertex | 1 | $125 |
| Pfizer | 5 | $123 |
| Gilead | 6 | $94 |
| Ferring Pharmaceuticals Inc. | 6 | $87 |
| Aimmune Therapeutics, Inc. | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Shionogi Inc | 2 | $50 |
| Intercept Pharmaceuticals, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Sanofi | 1 | $25 |
| Novo Nordisk | 1 | $22 |
| Celltrion USA Inc. | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $16 |
| Mauna Kea Technologies, Inc. | 1 | $13 |
| Braintree Laboratories, Inc. | 1 | $11 |
How this compares
$2,655 in reported general payments places this provider in the 45th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 12 | $41,005 |
| ViberziEluxadoline | 12 | $19,317 |
| VemlidyTenofovir Alafenamide | 11 | $14,862 |
| Mesalamine | 15 | $5,327 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 20 | $3,393 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 47 | $2,726 |
| Esomeprazole Magnesium | 16 | $2,122 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 91 | $1,256 |
| Omeprazole | 80 | $1,066 |
| Famotidine | 71 | $1,006 |
| Pantoprazole Sodium | 26 | $438 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $171 |
| Metronidazole | 13 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Viberzi | $162 | $60,32224 claims |
| GileadVemlidy | $94 | $14,86211 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $87 | $3,39320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Greenbelt
- Apurva ModiRockville$1.1M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Zachary BormanChevy Chase$520K
- Mouen KhashabBaltimore$440K
- Erica CohenChevy Chase$385K
- Natarajan RavendhranCatonsville$367K
- Raymond CrossBaltimore$341K
- Raja TaunkAnnapolis$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.